HuGE Literature Finder
Records
1
-
3
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology (Baltimore, Md.) 2016 Jan . Kwo Paul, Gitlin Norman, Nahass Ronald, Bernstein David, Etzkorn Kyle, Rojter Sergio, Schiff Eugene, Davis Mitchell, Ruane Peter, Younes Ziad, Kalmeijer Ronald, Sinha Rekha, Peeters Monika, Lenz Oliver, Fevery Bart, De La Rosa Guy, Scott Jane, Witek Jam |
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver international : official journal of the International Association for the Study of the Liver 2015 Feb 35 (2): 417-21. Zeuzem Stefan, Dufour Jean-François, Buti Maria, Soriano Vicente, Buynak Robert J, Mantry Parvez, Taunk Jawahar, Stern Jerry O, Vinisko Richard, Gallivan John-Paul, Böcher Wulf, Mensa Federico J, |
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England journal of medicine 2014 Jan 370 (3): 211-21. Sulkowski Mark S, Gardiner David F, Rodriguez-Torres Maribel, Reddy K Rajender, Hassanein Tarek, Jacobson Ira, Lawitz Eric, Lok Anna S, Hinestrosa Federico, Thuluvath Paul J, Schwartz Howard, Nelson David R, Everson Gregory T, Eley Timothy, Wind-Rotolo Megan, Huang Shu-Pang, Gao Min, Hernandez Dennis, McPhee Fiona, Sherman Diane, Hindes Robert, Symonds William, Pasquinelli Claudio, Grasela Dennis M, |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: